GlassScriptPhysician profile
Payam Saadat
NPI 1740487925
$116,158.17
in general payments reported to CMS, 2019-2025
40 companies · $20K in 2025
The $20K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $1,744 · 2021: $5,554 · 2022: $23K · 2023: $16K · 2024: $24K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Food and Beverage: $12K · Travel and Lodging: $3,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,625.00 |
| Food and Beverage | $11,735.50 |
| Travel and Lodging | $3,885.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $70,195.19 | 2021-2025 | Opzelura, Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27,497.70 | 2019-2025 | Siliq, Jublia, Cabtreo |
| Regeneron Healthcare Solutions, INC. | $3,430.22 | 2019-2025 | Libtayo, Dupixent |
| Abbvie INC. | $2,465.90 | 2019-2025 | Skyrizi, Rinvoq |
| Mimedx Group, INC. | $1,472.91 | 2024-2025 | |
| Genzyme Corporation | $1,263.92 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,232.13 | 2019-2025 | |
| Strata Skin Sciences, INC. | $1,048.27 | 2019-2025 | Xtrac |
| Sun Pharmaceutical Industries INC. | $1,040.42 | 2019-2025 | Ilumya, Winlevi, Odomzo |
| Galderma Laboratories, L.P. | $1,021.79 | 2019-2025 | Aklief, Nemluvio, Twyneo |
| Dermavant Sciences, INC. | $790.22 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $571.62 | 2019-2023 | Tremfya |
| Leo Pharma INC. | $550.18 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $530.89 | 2019-2025 | Bimzelx, Cimzia |
| Epi Health, LLC | $359.18 | 2019-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $314.29 | 2020-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $277.66 | 2019-2025 | |
| Almirall LLC | $248.49 | 2019-2023 | Klisyri |
| Lilly USA, LLC | $189.43 | 2019-2022 | |
| Pfizer INC. | $183.47 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $176.04 | 2022-2024 | Sotyktu |
| Organon LLC | $159.91 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.85 | 2022-2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $123.36 | 2023-2025 | Zoryve |
| Allergan, INC. | $103.10 | 2019-2022 | |
| Genentech USA, INC. | $90.95 | 2019-2022 | |
| Celgene Corporation | $79.45 | 2019 | |
| Sanofi-Aventis U.S. LLC | $73.64 | 2019 | |
| Sandoz INC. | $68.79 | 2019 | |
| Verrica Pharmaceuticals INC. | $67.21 | 2025 | Ycanth |
| Vyne Pharmaceuticals INC. | $62.09 | 2020-2021 | |
| Surgenex LLC | $47.31 | 2025 | Renograft, Surgraft, Ardeograft |
| Biofrontera INC. | $42.00 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $41.52 | 2019 | |
| Botanix Sb INC | $33.81 | 2025 | Sofdra |
| Medimetriks Pharmaceuticals, INC. | $32.00 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $30.86 | 2023 | Valchlor |
| Encore Dermatology INC. | $28.49 | 2019-2020 | |
| Dermira, INC. | $24.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payam Saadat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.